Hims & Hers Health, Inc. Class A Common Stock (HIMS)

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.

A Reddit user claims to have turned disaster into triumph after nearly blowing his mother's $800,000 retirement account.

Bank of America names its highest-conviction stock ideas for Q3 2025—8 Buys and 2 Underperforms. Boeing, Cisco, and Datadog top the list.

The telehealth company stated that its entry to Canada will come as generic semaglutide hits the market for the first time.

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 4.1% in the morning session after the company announced plans to expand into Canada with a weight-loss solution centered on generic semaglutide. The telehealth company intends to launch its weight loss program in Canada in 2026, a move timed to coincide with the expected global debut of a generic version of semaglutide. Semaglutide is the active ingredient in popular and effective, but costly, branded weight-loss drugs like Ozempic and Wegovy. Hims & Hers aims to capture a significant portion of the Canadian market, where the company notes that about two-thirds of adults are overweight or obese. 

Hims & Hers announced plans to expand its weight loss program to Canada in 2026 in connection with the availability of generic semaglutide anywhere in the world.

Small caps outshine tariff fears as Russell 2000 nears all-time highs. Oklo, NuScale, Hims lead with gains of over 95% YTD despite trade turmoil.

Hims & Hers faces stock pressure after Novo Nordisk ends Wegovy access, citing compounding violations and marketing concerns.

Popular obesity treatments Wegovy and Zepbound are seeing price reductions, but patients still face significant barriers to sustained access.

A clean balance sheet can signal disciplined management and stability. It also means a company can expand and thrive without relying on borrowed capital.

Hims & Hers stock dipped after Novo Nordisk pulled back its partnership for a weight loss drug distribution, though that may not mean much.

A look at the top 20 most-searched tickers on Benzinga Pro for the first six months of 2025.

A look at the top 20 most-searched stock tickers for the month of June on Benzinga Pro.

Amazon's latest data center will reportedly require the same amount of electricity as 1 million homes.

Last week's worst performers include CRCL, HIMS, VG, QXO, CRWV, DUOL, EQIX, EQNR, CF, and EC. Are they in your portfolio?

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.